Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

By sjmartinez • November 3, 2023

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March L, Singh JA, Suarez-Almazor ME, Boers M, Stevens RM, Furst DE, Woodworth T, Leong A, Brooks PM, Flurey C, Christensen R; OMERACT Safety Working Group. Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group. Semin Arthritis Rheum. 2023 Oct 26;63:152288. doi: 10.1016/j.semarthrit.2023.152288. Epub ahead of print. PMID: 37918049.

Tags: Adverse events, Core outcome set, Harms, OMERACT, Publications, Rheumatology, rheumatology, safety

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]

The malate-aspartate shuttle supports thermogenic lipid mobilization in brown adipocytes

Veliova M, Ferreira CM, Montales KP, Villalobos F, Brownstein AJ, Acín-Pérez R, Ferreira GS, Jones AE, Stiles L, Divakaruni AS, Liesa M, Shirihai OS, Oliveira[...]

Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus in Two Southern California Counties

Pak K, Leng M, Nguyen J, Moussa K, Gish R, Han SH, Pockros P. Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus[...]